10106196A Flexible Molecular Platform for Agile and Scalable Cell PurificationClosedCollaborative R&DInnovate UKCell therapies are the next generation of medicines that can potentially cure many diseases including diabetes, heart disease or cancer. While there are some promising approaches already, bringing these treatments to broad application requires improvements in the scale and cost. Pluripotent stem cell derived therapies have the power to do this and can be the key to treat some illnesses that are without a cure so far. However, making the right cell types (e.g. pancreatic cells, heart cells or immune cells) from stem cells can be difficult and lead to some unwanted cells that are either not beneficial for the patient or, in the worst case, can be dangerous. Therefore we need to make sure that cells for therapeutic purposes are clean and safe to use. Plurify is developing a new approach to ensure exactly that. With our technology, we can purify any specific cell type from a mixture of cells that is usually produced when trying to make cells for therapy. This new method can solve one of the key bottlenecks that have been holding back pluripotent stem cells from fulfilling their true potential for cell therapies. With the help of Innovate UK funding, we will be able to develop this technology into an efficient platform that can be applied quickly to many different cell types and make it possible to produce a lot of different cell therapies in the future. What's even better is that our approach is also reducing waste and failures in manufacturing, leading to a more efficient and sustainable process of producing these new cell therapies. This will in turn save costs and make sure that these treatments can reach as many people as possible. In conclusion, Plurify will solve a key bottleneck to enable more efficient manufacturing of purer cell therapy products for lower cost so that more and more people can benefit from this next generation of therapies in the near future.